Phaseline

Targets › TPZM

TPZM: drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on TPZM, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TeclisonTrans-arterial tirapazamine embolization (TATE)
Hypoxia-activated prodrug embolized intra-arterially to deliver tirapazamine to liver tumo
TPZMPhase 2Hepatocellular CarcinomaDec 2026

Conditions

Hepatocellular Carcinoma (2)

Modalities

mixed (1)

Companies

Teclison (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.